Related Experiment Videos
Anakinra's efficacy is variable in refractory gout: report of ten cases
Kun Chen1, Theodore Fields, Carol A Mancuso
1Rheumatology Division, Weill Cornell Medical College, Hospital for Special Surgery, New York, NY, USA. chenk@hss.edu
Objectives:
To evaluate the efficacy of anakinra for patients with acute gout.
Methods:
We reviewed the charts of 10 patients who received anakinra for urate crystal-induced arthritis at the Hospital for Special Surgery since 2007. Demographic information, comorbidities, short-term treatment outcomes, and subsequent flares were reviewed.
Results:
Patients in our study had a high prevalence of comorbidities. All patients received corticosteroids before anakinra treatment. The mean number of anakinra injections was 3.2 per patient (100 mg subcutaneously per day). Six patients had a good response. Three patients had a partial response and 1 patient had no response. Nine patients had documented recurrent flares after discontinuing anakinra (ranging from 3 to 45 days after).
Conclusion:
Anakinra is a therapeutic option for patients with acute urate crystal-induced arthritis who do not respond to or have a contraindication to traditional treatments. Although a short course of anakinra resulted in favorable outcomes for some of our patients, response rates were poorer in our study than in previously published reports, and relapses were common.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...